← Markets

AbCellera Biologics Inc.

ABCL · NASDAQ

Market closed$6.47$0.305000 (+4.95%)After hours $6.50 · +0.54%

Key statistics

Previous close$6.16
Open$5.93
Day high$6.55
Day low$5.93
52-week high$8.44
52-week low$2.75
Market cap1.97B
Volume4.22M
Average volume8.13M
P/E ratio-13.47
Forward P/E—
EPS-0.48
Dividend yield0.00%

Market context

Why it moved

AbCellera Biologics (ABCL) shares rose today as Cantor Fitzgerald reiterated its Overweight rating with an $11.00 price target, highlighting the upcoming Phase 2 data readout for ABCL635 in vasomotor symptoms as a potential major catalyst with significant upside, helping the stock recover from recent profit-taking pressure following its strong year-to-date rally.

NetStockinvestInvesting.comJustsecurityFacebook

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026AbCellera Biologics surged nearly 5% as the AI-driven drug discovery narrative gains renewed investor attention, with the company cited as a sector standout — up roughly 76% year to date — following a Q1 revenue beat and positive interim Phase 1 data for its lead pipeline programs. With Q2 earnings approaching and analysts raising price targets on the back of its GPCR platform progress and advancing women's health trial ABCL635, investors are increasingly viewing AbCellera's cash-rich balance sheet (over $650M in liquidity vs. ~$1.6B market cap) as an attractive foundation for a platform-to-pipeline transition.

4.9513

July 17, 2026AbCellera Biologics shares tumbled nearly 9%, pulling back sharply from recent highs, even as the broader healthcare sector saw mixed signals. The decline comes ahead of a closely watched Q2 earnings report due July 22, with investors weighing recent positive catalysts — including a Benchmark upgrade to Buy, the addition of board director Lynn Seely, and a 52-week high hit in late June — against ongoing concerns about the company's cash burn and unprofitability. Analysts remain cautiously optimistic, pointing to upcoming pivotal Phase 2 data for lead menopause candidate ABCL635 and Phase 1 progress for ABCL575 as the key catalysts that could rerate the stock.

-8.6053

July 16, 2026AbCellera Biologics closed essentially unchanged as investors await the company's upcoming earnings report and pipeline catalysts, with shares holding near their 52-week high. Recent momentum has been driven by Benchmark's upgrade to Buy, the appointment of Lynn Seely to the board, and growing analyst optimism around pivotal Phase 2 data for ABCL635, its non-hormonal menopause treatment. With over $650M in liquidity and a consensus analyst price target near $10, bulls view the stock as an asymmetric bet trading near cash value, while the broader healthcare sector benefits from UBS's upgraded outlook on biotech M&A and AI-driven drug discovery.
July 15, 2026AbCellera Biologics rose sharply, buoyed by a recent Benchmark analyst upgrade to Buy with an $11 price target and growing anticipation for pivotal Phase 2 data on ABCL635 — its non-hormonal menopause treatment — expected in Q3 2026. A partnership with Jazz Pharmaceuticals for multispecific oncology antibodies has further validated the platform's commercial reach, while 65 institutional investors added positions last quarter. The stock is trading well above its 52-week low of $2.75, up over 50% in the past year, with investors viewing the AI-driven discovery platform and $650M+ liquidity cushion as asymmetric upside ahead of clinical catalysts.

3.3742

July 14, 2026AbCellera Biologics closed down over 4% as shares pulled back amid below-average volume, consolidating after a strong run driven by recent catalysts. Investor focus remains on the upcoming Phase 2 data for lead candidate ABCL635 (a non-hormonal menopause treatment) expected in Q3 2026, a new partnership with Jazz Pharmaceuticals validating its multispecific oncology drug capabilities, and a fresh Buy upgrade from Benchmark with an $11 price target on July 7. The broader biotech sector has been a strong performer, with Goldman Sachs projecting continued rally on M&A and innovation tailwinds.

-4.1176

July 11, 2026AbCellera Biologics tumbled nearly 7% as profit-taking swept in following a sharp multi-week rally that had pushed shares to 52-week highs on the back of a new multi-program discovery deal with Jazz Pharmaceuticals and encouraging Phase 1 data for ABCL635, its non-hormonal menopause candidate. The selloff reflects a classic sell-the-news reaction despite recent analyst price target hikes, board additions, and broader biotech sector strength — with Q2 earnings scheduled for August 5 as the next major catalyst for investors. In after-hours trading, shares recovered modestly to $6.88.

-6.7215

July 10, 2026AbCellera Biologics rose nearly 3%, buoyed by a broader healthcare sector tailwind and growing biotech M&A optimism after Jim Cramer called biotech "the hottest group in the market" and predicted a wave of acquisition deals following a more favorable regulatory environment under new FDA leadership. The gains came as healthcare has been the top-performing S&P 500 sector over recent weeks, with XLV up over 6% in June alone. AbCellera also recently appointed Dr. Lynn Seely to its board and announced Q2 2026 earnings on August 5, keeping investor focus on the company's clinical pipeline, particularly lead candidate ABCL635 for menopausal symptoms, ahead of the next earnings catalyst.

2.6761

July 9, 2026AbCellera Biologics tumbled nearly 8% amid a broad market risk-off selloff triggered by President Trump declaring the U.S.-Iran interim deal 'over,' sending oil prices surging over 5% and rattling equities globally. The decline came despite constructive company-specific news, including AbCellera's announcement that it will report Q2 2026 results on August 5 and last week's appointment of Lyell CEO Lynn Seely to its board. Longer-term, the biotech sector had been a standout amid rotation out of crowded semiconductors, with Jim Cramer calling biotech 'the hottest group in the market' and predicting an M&A wave under the new FDA leadership — a narrative that could benefit AbCellera given analyst views framing it as an asymmetric acquisition target with $650M+ in liquidity.

-7.6723

Investing.com South Africa · July 17, 2026Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11 By Investing.comQuiver Quantitative · July 11, 2026AbCellera Biologics Stock (ABCL) Opinions on Jazz Partnership and Analyst UpgradeBusiness Wire · July 7, 2026AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026Moomoo · June 26, 2026JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13StocksToTrade · June 25, 2026ABCL Stock Pops As Jazz Deal Fuels Oncology AmbitionsPR Newswire · June 17, 2026Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific AntibodiesStock Titan · June 17, 2026Jazz, AbCellera line up $56M now and up to $792M per cancer programStocktwits · May 9, 2026ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost
Benzinga · July 7, 2026Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price Target
Mt Newswire · July 7, 2026Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target is $11
Benzinga · June 17, 2026Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Mt Newswire · June 17, 2026Jazz Pharmaceuticals, AbCellera Biologics to Collaborate on T-cell Engaging Multispecific Antibodies
Benzinga · June 17, 2026Jazz Pharma And AbCellera Announce Preclinical Research Collaboration, Option And License Agreement To Discover, Develop Next-Gen T-Cell Engaging Multispecific Antibodies
Mt Newswire · May 11, 2026Earnings Flash (ABCL) AbCellera Biologics Posts Q1 Per Share Loss of $0.14, vs. FactSet Est Loss $0.17
Mt Newswire · May 11, 2026AbCellera Biologics Q1 Loss Narrows, Revenue Rises
Benzinga · May 11, 2026AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate

Peers

S&P 500SPX · $7,457.69-1.01%Apogee Therapeutics, Inc.APGE · $134.00-0.06%Immunovant, Inc.IMVT · $40.26+3.34%Mirum Pharmaceuticals, Inc.MIRM · $118.86+1.28%Genmab A/SGMAB · $28.72-0.90%Ligand Pharmaceuticals IncorporatedLGND · $303.39+2.34%Evotec SEEVO · $1.96-0.51%Charles River Laboratories International, Inc.CRL · $224.35-2.10%WuXi Biologics (Cayman) Inc.2269.HK · 36.98-5.95%Ionis Pharmaceuticals, Inc.IONS · $54.39-0.48%Regeneron Pharmaceuticals, Inc.REGN · $676.69-0.33%Alnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%